Read about both of NxGEN’s gene therapy platforms:
1) NxGEN’s CpG-depletion technology of the AAV vector to achieve safe, effective, and durable
therapeutic gene expression.
2) NxGEN’s cardiac gene therapy to modulate the immune system to prevent chronic rejection without
the requirement for life-long anti-rejection medication, which can also be used for inflammatory
diseases.
Click here to read the Article in GEN Magazine.
December 8th, 2022 - NxGEN Vector Solutions is featured in December’s issue of GEN Magazine in the article, “Viral Vectors for Gene Therapy Get the Industrial Design Treatment.”
